DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • China
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
600664 logo

Harbin Pharmaceutical Group Co., Ltd. Stock Price

SHSE:600664 Community·CN¥23.9b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

600664 Share Price Performance

CN¥0
-3.73 (-100.00%)
​
CN¥0
-3.73 (-100.00%)
​
Price CN¥0
Wed, 2 Sep 26
Share Pricen/a

600664 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with questionable track record.

1 Risk
1 Reward
View Full Analysis

Harbin Pharmaceutical Group Co., Ltd. Key Details

CN¥16.1b

Revenue

CN¥12.0b

Cost of Revenue

CN¥4.1b

Gross Profit

CN¥3.6b

Other Expenses

CN¥512.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Sep 10, 2026
0.20
25.57%
3.17%
18.5%
View Full Analysis

About 600664

Founded
1991
Employees
10039
CEO
Chuanyou Lu
WebsiteView website
www.hayao.com

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, antiviral and anti-infective, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, human erythropoietin injections, iron and vitamin B12 oral solutions, calcium, iron, and zinc oral solutions, ceftriaxone sodium injections, Qufenggutong gel ointment, GNC Vitapak nutritional pack, lacidipine tablets, GNC fish oil capsules, coenzyme Q10 and panthenol soft capsules, GNC children's liquid calcium magnesium zinc, penicillin sodium, acetaminophen and chlorpheniramine maleate granules, glucosamine chondroitin calcium tablets, ceftriaxone sodium for injection, GNC milk thistle extract tablets and capsules, and compound sulfamethoxazole oral tablets. The company is also involved in culture, science and technology, pharmaceutical commercial and industry, property, and investment activities. Harbin Pharmaceutical Group Co., Ltd. was founded in 1991 and is based in Harbin, China.

Recent 600664 News & Updates

Recent updates

No updates

Harbin Pharmaceutical Group Co., Ltd. Competitors

603259 logo

WuXi AppTec

Symbol: SHSE:603259
Market cap: CN¥458.5b
600276 logo

Jiangsu Hengrui PharmaceuticalsLtd

Symbol: SHSE:600276
Market cap: CN¥304.3b
688506 logo

Sichuan Biokin PharmaceuticalLtd

Symbol: SHSE:688506
Market cap: CN¥107.3b
000538 logo

Yunnan Baiyao GroupLtd

Symbol: SZSE:000538
Market cap: CN¥90.4b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide